Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving Airway Clearance for Children With Neurologic Impairment Hospitalized With Pneumonia.

Hospital pediatrics·2026
Same author

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.

Cancer chemotherapy and pharmacology·2025
Same author

Drug-induced metabolic remodeling of immune cell repertoire generates an effective broad-range antimicrobial effect.

Research square·2025
Same author

Effects of an intergenerational Kindermusik class on stress and affect in older adults with dementia and their caregivers: a pilot study using ecological momentary assessment.

Frontiers in aging·2025
Same author

Genome-wide analysis of Smad and Schnurri transcription factors in <i>C. elegans</i> demonstrates widespread interaction and a function in collagen secretion.

eLife·2025
Same author

Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis.

Diabetes & metabolism·2025

Related Experiment Video

Updated: May 20, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Sitagliptin exerts an antinflammatory action.

Antoine Makdissi1, Husam Ghanim, Mehul Vora

  • 1Division of Endocrinology, Diabetes, and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, New York 14209, USA.

The Journal of Clinical Endocrinology and Metabolism
|June 30, 2012
PubMed
Summary
This summary is machine-generated.

Sitagliptin, an antidiabetic drug, demonstrated significant anti-inflammatory effects in patients with type 2 diabetes. Treatment reduced key inflammatory markers, suggesting potential benefits beyond glucose control.

Related Experiment Videos

Last Updated: May 20, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Sitagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor used for type 2 diabetes.
  • DPP-IV (CD26) is involved in incretin degradation and mediates inflammatory signals.
  • This study investigated the potential anti-inflammatory effects of sitagliptin.

Purpose of the Study:

  • To evaluate the anti-inflammatory properties of sitagliptin in patients with type 2 diabetes.
  • To assess the impact of sitagliptin on inflammatory markers and CD26 expression.

Main Methods:

  • A 12-week randomized, placebo-controlled trial involving 22 patients with type 2 diabetes.
  • Patients received either 100 mg daily sitagliptin or placebo.
  • Fasting blood samples were analyzed at various time points for inflammatory markers and gene/protein expression.

Main Results:

  • Sitagliptin significantly reduced glycosylated hemoglobin and increased glucagon-like peptide-1 levels.
  • Treatment led to significant reductions in CD26, TNFα, TLR-4, TLR-2, JNK-1, IKKβ, and CCR-2 mRNA expression.
  • Protein expression of JNK-1, IKKβ, TLR-4, and plasma levels of CRP, IL-6, and free fatty acids also decreased.

Conclusions:

  • Sitagliptin exhibits potent and rapid anti-inflammatory effects.
  • These effects may contribute to inhibiting atherosclerosis.
  • Suppression of CD26 suggests sitagliptin may inhibit DPP-IV synthesis, not just its action.